Here, we describe the development and characterization of the PRL-humanized NSG-Pro mouse model, which is the first PDX recipient strain to support the engraftment, growth, metastatic progression, and the development of resistance to clinically relevant therapies across diverse breast cancer subtypes, in particular therapy-naïve ER+ tumors. The gene discussed is PRL; the disease is breast cancer.